Due to the limitations of AFP as an HCC screening biomarker, novel biomarkers such as AFP-L3%, des-gamma-carboxy prothrombin (DCP), osteopontin, glycosylated proteins, and circulating tumor cells have been discovered and studied as individual and combination testing [50]. This evidence concerns the gene AFP and neoplasm.